ANDRAŠINA, Tomáš, Jiří PÁNEK, Jan HLAVSA, Vladan BERNARD and Vlastimil VÁLEK. Endoluminal radiofrequency ablation of hilarcholangiocarcinoma. In ESGAR 2016. 2016. Available from: https://dx.doi.org/10.1007/s13244-016-0502-9.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Endoluminal radiofrequency ablation of hilarcholangiocarcinoma
Authors ANDRAŠINA, Tomáš (703 Slovakia, guarantor, belonging to the institution), Jiří PÁNEK (203 Czech Republic, belonging to the institution), Jan HLAVSA (203 Czech Republic), Vladan BERNARD (203 Czech Republic, belonging to the institution) and Vlastimil VÁLEK (203 Czech Republic, belonging to the institution).
Edition ESGAR 2016, 2016.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30224 Radiology, nuclear medicine and medical imaging
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW ESGAR Book of abstracts 2016
RIV identification code RIV/00216224:14110/16:00088926
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1007/s13244-016-0502-9
Keywords (in Czech) radiofrekvenční ablace; rakovina žlučových cest; perkutánní drenáže
Keywords in English radiofrequency ablation; biliary cancer; percutaneous drainage
Changed by Changed by: MUDr. Tomáš Andrašina, Ph.D., učo 51232. Changed: 26/1/2019 21:05.
Abstract
Purpose: To prove efficacy of endoluminal radiofrequency ablation in palliative treatment of hilar cholangiocarcinoma. Material and methods: 35 patients with hilar cholangiocarcinoma have been enrolled in a prospective randomised study since 2010. The infiltrative type of cholangiocarcinoma was predominant. 65 non-covered self-expandable metal stents were inserted. In group A (n=18) the endoluminal ablation with a bipolar radiofrequency catheter (EndoHPB; EMcision Ltd., London, UK) was performed 0-48 hours prior to the stent insertion, in group B (n=17) the stent was implanted without a prior ablation. The primary endpoints of the study were to determine the rate of complications, duration of stent patency and survival of patients (Kaplan-Meier analysis). Results: The rate of biochemical pancreatitis, which was resolved in 3 days after stent insertion, was significantly higher in group A. The average primary stent patency was 5.9 and 5.7 months in groups A and B, respectively; 3-month and 6-month stent failure was 0% and 6.1% in group A and 6.3% and 25% in group B. The median survival from the initial drainage was 12.3 (6.7- 20.1) and 12.8 (5.7-14.7) months in groups A and B, respectively. Conclusion: The effect of an endoluminal ablation on patients survival was not proven in the prospective randomised clinical study. However, in the group of patients undergoing ablation there is a tendency of a lower rate of early stent failure. The intervention should be associated with very mild biochemical pancreatitis.
Links
MUNI/A/1083/2015, interní kód MUName: Radiologické diagnostické a intervenční postupy u onkologických pacientů a jejich přínos v rámci komplexní onkologické léčby s důrazem na farmakoekonomické aspekty.
Investor: Masaryk University, Category A
NV15-32484A, research and development projectName: Využití nových biotechnologií v prevenci a léčbě stenóz žlučových cest
PrintDisplayed: 27/5/2024 16:01